Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: A new method of monitoring treatment?

European Radiology

Volumn 20, Issue 12, 2010, Pages 2890-2898

  Lind, Joline S W ^a   Meijerink, Martijn R ^a   Dingemans, Anne Marie C ^b   Van Kuijk, Cornelis ^a   Öllers, Michel C ^b   De Ruysscher, Dirk ^b   Postmus, Pieter E ^a   Smit, Egbert F ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dynamic contrast enhanced CT; Erlotinib; Non small cell lung cancer; Sorafenib; Tumour perfusion

Indexed keywords

ERLOTINIB; SORAFENIB;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; PERFUSION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BLOOD FLOW; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, NON-SMALL-CELL LUNG; CONTRAST MEDIA; FEMALE; HUMANS; IOHEXOL; LUNG NEOPLASMS; MALE; PROGNOSIS; PYRIDINES; QUINAZOLINES; RADIOGRAPHIC IMAGE ENHANCEMENT; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 78650304662     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-010-1869-5     Document Type: Article

References (40)

1. D Hanahan RA Weinberg 2000 The hallmarks of cancer Cell 100 57 70 1:CAS:528:DC%2BD3cXks1CktA%3D%3D 10.1016/S0092-8674(00)81683-9 10647931
2. P Therasse 2002 Measuring the clinical response. What does it mean? Eur J Cancer 38 1817 1823 1:STN:280:DC%2BD38vkslyntw%3D%3D 10.1016/S0959-8049(02) 00182-X 12204662 (Pubitemid 35256090)
3. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
4. EA Eisenhauer P Therasse J Bogaerts LH Schwartz D Sargent R Ford J Dancey S Arbuck S Gwyther M Mooney L Rubinstein L Shankar L Dodd R Kaplan D Lacombe J Verweij 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228 247 1:STN:280: DC%2BD1M%2Fgs12rug%3D%3D 10.1016/j.ejca.2008.10.026 19097774
5. SB Fox AL Harris 2004 Histological quantitation of tumour angiogenesis APMIS 112 413 430 10.1111/j.1600-0463.2004.apm11207-0803.x 15563306 (Pubitemid 39626050)
6. MR Meijerink H van Cruijsen K Hoekman M Kater C van Schaik JH van Waesberghe G Giaccone RA Manoliu 2007 The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients Eur Radiol 17 1700 1713 10.1007/s00330-006-0425-9 17072618 (Pubitemid 46909659)
7. CG Willett Y Boucher E di Tomaso DG Duda LL Munn RT Tong DC Chung DV Sahani SP Kalva SV Kozin M Mino KS Cohen DT Scadden AC Hartford AJ Fischman JW Clark DP Ryan AX Zhu LS Blaszkowsky HX Chen PC Shellito GY Lauwers RK Jain 2004 Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 145 147 1:CAS:528: DC%2BD2cXoslKmtQ%3D%3D 10.1038/nm988 14745444 (Pubitemid 38524883)
8. HQ Xiong R Herbst SC Faria C Scholz D Davis EF Jackson T Madden D McConkey M Hicks K Hess CA Charnsangavej JL Abbruzzese 2004 A phase I surrogate endpoint study of SU6668 in patients with solid tumors Invest New Drugs 22 459 466 1:CAS:528:DC%2BD2cXmt1ajsL4%3D 10.1023/B:DRUG.0000036688.96453.8d 15292716 (Pubitemid 39619822)
9. JP Thomas RZ Arzoomanian D Alberti R Marnocha F Lee A Friedl K Tutsch A Dresen P Geiger J Pluda W Fogler JH Schiller G Wilding 2003 Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors J Clin Oncol 21 223 231 1:CAS:528: DC%2BD2cXpsVWqsrc%3D 10.1200/JCO.2003.12.120 12525513 (Pubitemid 46606150)
10. MI Koukourakis I Mavanis G Kouklakis M Pitiakoudis G Minopoulos C Manolas C Simopoulos 2007 Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging Am J Clin Oncol 30 315 318 1:CAS:528:DC%2BD2sXnvVGiurc%3D 10.1097/01.coc. 0000258119.90805.ca 17551312 (Pubitemid 46884155)
11. QS Ng V Goh H Fichte E Klotz P Fernie MI Saunders PJ Hoskin AR Padhani 2006 Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements Radiology 239 547 553 10.1148/radiol.2392050568 16543594
12. QS Ng V Goh E Klotz H Fichte MI Saunders PJ Hoskin AR Padhani 2006 Quantitative assessment of lung cancer perfusion using MDCT: does measurement reproducibility improve with greater tumor volume coverage? AJR Am J Roentgenol 187 1079 1084 10.2214/AJR.05.0889 16985160 (Pubitemid 44453967)
13. U Tateishi H Nishihara S Watanabe T Morikawa K Abe K Miyasaka 2001 Tumor angiogenesis and dynamic CT in lung adenocarcinoma: radiologic-pathologic correlation J Comput Assist Tomogr 25 23 27 1:STN:280:DC%2BD3M7gvVyisg%3D%3D 10.1097/00004728-200101000-00004 11176288 (Pubitemid 32099203)
14. Y Li ZG Yang TW Chen HJ Chen JY Sun YR Lu 2008 Peripheral lung carcinoma: correlation of angiogenesis and first-pass perfusion parameters of 64-detector row CT Lung Cancer 61 44 53 10.1016/j.lungcan.2007.10.021 18055062 (Pubitemid 351862323)
15. Lind JS, Dingemans AM, Groen HJ, Thunnissen FB, Bekers O, Heideman DA, Honeywell RJ, Giovannetti E, Peters GJ, Postmus PE, van Suylen RJ, Smit EF. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010 Jun 1;16(11):3078-87
16. GR Blumenschein Jr U Gatzemeier F Fossella DJ Stewart L Cupit F Cihon J O'Leary M Reck 2009 Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer J Clin Oncol 27 4274 4280 1:CAS:528:DC%2BD1MXht1WisbjP 10.1200/JCO.2009.22.0541 19652055
17. B Liu T Barrett P Choyke K Maynard J Wright S Kummar A Murgo J Doroshow M Gutierrez B Nci 2006 A phase II study of BAY 43-9006 (sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC) J Clin Oncol (Meeting Abstracts) 24 17119
18. JH Schiller JW Lee NH Hanna AM Traynor DP Carbone 2008 A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501 J Clin Oncol (Meeting Abstracts) 26 8014
19. FA Shepherd PJ Rodrigues T Ciuleanu EH Tan V Hirsh S Thongprasert D Campos S Maoleekoonpiroj M Smylie R Martins M van Kooten M Dediu B Findlay D Tu D Johnston A Bezjak G Clark P Santabarbara L Seymour 2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123 132 1:CAS:528:DC%2BD2MXmtFaksbo%3D 10.1056/NEJMoa050753 16014882 (Pubitemid 41058344)
20. SJ Crabb D Patsios E Sauerbrei PM Ellis A Arnold G Goss NB Leighl FA Shepherd J Powers L Seymour SA Laurie 2008 Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer J Clin Oncol 27 404 410 10.1200/JCO.2008.16.2545 19047292
21. Zankl M, Panzer W, Drexel G (1993) Tomographic anthropomorphic models II. Organ doses from tomographic examinations. GSF report 30/93. Neuherberg, Germany
22. Zankl M, Panzer W, Drexel G (1991) The calculation of dose from external photon exposures using reference humans and Monte Carlo methods IV. Organ doses from tomographic examinations. GSF report 30/91. Neuherberg, Germany
23. G Stamm HD Nagel 2002 CT-expo-a novel program for dose evaluation in CT Rofo 174 1570 1576 1:STN:280:DC%2BD38jgvFOitQ%3D%3D 12471531
24. Y Tsushima S Funabasama S Sanada J Aoki K Endo 2002 Development of perfusion CT software for personal computers Acad Radiol 9 922 926 10.1016/S1076-6332(03)80462-2 12186441 (Pubitemid 34856285)
25. Y Tsushima S Funabasama J Aoki S Sanada K Endo 2004 Quantitative perfusion map of malignant liver tumors, created from dynamic computed tomography data Acad Radiol 11 215 223 10.1016/S1076-6332(03)00578-6 14974597 (Pubitemid 38140292)
26. M Zhang M Kono 1997 Solitary pulmonary nodules: evaluation of blood flow patterns with dynamic CT Radiology 205 471 478 1:STN:280:DyaK1c%2FhvFCntg%3D%3D 9356631 (Pubitemid 27467328)
27. F Kiessling J Boese C Corvinus JR Ederle I Zuna SO Schoenberg G Brix A Schmahl S Tuengerthal F Herth HU Kauczor M Essig 2004 Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization and treatment monitoring? Eur Radiol 14 1226 1233 1:STN:280:DC%2BD2czhvVKnuw%3D%3D 15029450
28. GY Ovali A Sakar C Goktan P Celik A Yorgancioglu N Nese Y Pabuscu 2007 Thorax perfusion CT in non-small cell lung cancer Comput Med Imaging Graph 31 686 691 10.1016/j.compmedimag.2007.08.005 17904334 (Pubitemid 47600614)
29. QS Ng V Goh D Carnell K Meer AR Padhani MI Saunders PJ Hoskin 2007 Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer Int J Radiat Oncol Biol 67 1375 1380 1:CAS:528:DC%2BD2sXjs1Oju7w%3D 10.1016/j.ijrobp.2006.11.028 (Pubitemid 46467170)
30. CG Willett Y Boucher DG Duda E di Tomaso LL Munn RT Tong SV Kozin L Petit RK Jain DC Chung DV Sahani SP Kalva KS Cohen DT Scadden AJ Fischman JW Clark DP Ryan AX Zhu LS Blaszkowsky PC Shellito M Mino-Kenudson GY Lauwers 2005 Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients J Clin Oncol 23 8136 8139 10.1200/JCO.2005.02. 5635 16258121 (Pubitemid 46657433)
31. QS Ng V Goh J Milner MR Stratford LK Folkes GM Tozer MI Saunders PJ Hoskin 2007 Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study Lancet Oncol 8 111 118 1:CAS:528:DC%2BD2sXhtlSgt7g%3D 10.1016/S1470-2045(07)70001-3 17267325 (Pubitemid 46158370)
32. J Wang N Wu MD Cham Y Song 2009 Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy AJR Am J Roentgenol 193 1090 1096 10.2214/AJR.08.1367 19770333
33. RK Jain 2005 Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 58 62 1:CAS:528:DC%2BD2MXnvFar 10.1126/science.1104819 15637262 (Pubitemid 40093472)
34. F Winkler SV Kozin RT Tong SS Chae MF Booth I Garkavtsev L Xu DJ Hicklin D Fukumura E di Tomaso LL Munn RK Jain 2004 Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 6 553 563 1:CAS:528:DC%2BD2MXktVantw%3D%3D 15607960
35. SP Kloska T Fischer C Sauerland B Buerke R Dziewas R Fischbach W Heindel 2010 Increasing sampling interval in cerebral perfusion CT: limitation for the maximum slope model Acad Radiol 17 61 66 10.1016/j.acra.2009.07.009 19734063
36. A Kamena F Streitparth C Grieser L Lehmkuhl B Jamil K Wojtal J Ricke M Pech 2007 Dynamic perfusion CT: optimizing the temporal resolution for the calculation of perfusion CT parameters in stroke patients Eur J Radiol 64 111 118 10.1016/j.ejrad.2007.02.025 17383135 (Pubitemid 47418571)
37. V Goh J Liaw CI Bartram S Halligan 2008 Effect of temporal interval between scan acquisitions on quantitative vascular parameters in colorectal cancer: implications for helical volumetric perfusion CT techniques AJR Am J Roentgenol 191 W288 W292 10.2214/AJR.07.3985 19020217
38. KA Miles 2003 Perfusion CT for the assessment of tumour vascularity: which protocol? Br J Radiol 76 S36 S42 10.1259/bjr/18486642 15456712 (Pubitemid 39530314)
39. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
40. Sobin L, Wittekind Ch (eds) (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, New York, pp 99-103